Hematopoietic progenitors in cyclic neutropenia: effect of granulocyte colony-stimulating factor in vivo.

The number and growth factor requirements of committed progenitor cells (colony-forming units-granulocyte/macrophage and burst-forming units-erythroid) in three patients with cyclic neutropenia (two congenital, one acquired) were studied before and during therapy with recombinant human granulocyte colony-stimulating factor (G-CSF; 3 to 10 micrograms/kg/d). When the patients with congenital disease were treated with G-CSF, the cycling of blood cells persisted, but the cycle length was shortened from 21 days to 14 days, and the amplitude of variations in blood counts increased. There was a parallel shortening of the cycle and increase of the amplitude of variations (from two- to three-fold to 10- to 100-fold) in the number of both types of circulating progenitor cells in these two patients. In the patient with acquired cyclic neutropenia, cycling of both blood cells and progenitors could not be seen. In cultures deprived of fetal bovine serum, erythroid and myeloid bone marrow progenitor cells from untreated patients and from normals differed in growth factor responsiveness. As examples, maximal growth of granulocyte/macrophage (GM) colonies was induced by granulocyte/macrophage (GM)-CSF plus G-CSF in the patients, whereas a combination of GM-CSF, G-CSF and interleukin-3 (IL-3) was required in the normals, and erythropoietin alone induced fourfold more erythroid bursts from cyclic neutropenic patients than from normal donors (46% versus 11% of the maximal colony number, respectively). The growth factor responsiveness of marrow progenitor cells slightly changed during the treatment toward the values observed with normal progenitors. These results indicate that treatment with G-CSF not only ameliorated the neutropenia, but also increased the amplitude and the frequency of oscillation of circulating progenitor cell numbers. These data are consistent with the hypothesis that G-CSF therapy affects the proliferation of the hematopoietic stem cell.

[1]  H. Odeberg,et al.  Cell production and cell function in human cyclic neutropenia. , 2009, Scandinavian journal of haematology.

[2]  D. Wright,et al.  Abnormal responses of myeloid progenitor cells to granulocyte-macrophage colony-stimulating factor in human cyclic neutropenia. , 1989, The Journal of clinical investigation.

[3]  A. Faille,et al.  Cell kinetics in human cyclic neutropenia. , 2009, Scandinavian journal of haematology.

[4]  A. Theodore,et al.  Cycling of peripheral blood and marrow lymphocytes in cyclic neutropenia. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Gutterman,et al.  Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. , 1987, The New England journal of medicine.

[6]  A. Fauci,et al.  Human Cyclic Neutropenia: Clinical Review and Long-Term Follow-up of Patients , 1981, Medicine.

[7]  P. Greenberg,et al.  Alteration of colony‐stimulating factor output, endotoxemia, and granulopoiesis in cyclic neutropenia , 1976, American journal of hematology.

[8]  J. Adamson,et al.  Genomic cloning, characterization, and multilineage growth-promoting activity of human granulocyte-macrophage colony-stimulating factor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R D Lange,et al.  Cyclic hematopoiesis: human cyclic neutropenia. , 1983, Experimental hematology.

[10]  H. Broxmeyer,et al.  Oscillations of granulocytic and megakaryocytic progenitor cell populations in cyclic neutropenia in man. , 2009, Scandinavian journal of haematology.

[11]  A. Zander,et al.  Cyclic neutropenia and T lymphocyte suppression of granulopoiesis: abrogation of the neutropenic cycles by lithium carbonate. , 1982, Leukemia research.

[12]  P. Sehgal,et al.  Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. , 1988, Science.

[13]  C. Sieff.  Hematopoietic growth factors. , 1987, The Journal of clinical investigation.

[14]  J. Gabrilove,et al.  Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. , 1986, Science.

[15]  C. Eaves,et al.  Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. , 1978, Blood.

[16]  M. Green,et al.  EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.

[17]  R. Krance,et al.  Human cyclic neutropenia transferred by allogeneic bone marrow grafting. , 1982, Blood.

[18]  A. Migliaccio,et al.  Evidence for direct action of human biosynthetic (recombinant) GM-CSF on erythroid progenitors in serum-free culture. , 1987, Blood.

[19]  D. Metcalf,et al.  Monocyte Production of Colony Stimulating Factor in Familial Cyclic Neutropenia , 1974, British journal of haematology.

[20]  J. Villeval,et al.  Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. , 1988, Blood.

[21]  G. Rovera,et al.  Alteration of the Program of Terminal Differentiation Caused by Oncogenes in the Hemopoietic Progenitor Cell Line 32D C13 (G) a , 1989, Annals of the New York Academy of Sciences.

[22]  D. Dale,et al.  Cyclic neutropenia: a clinical review. , 1988, Blood reviews.

[23]  J. Gabrilove,et al.  Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium , 1989 .

[24]  Y. Sonoda,et al.  Analysis in serum-free culture of the targets of recombinant human hemopoietic growth factors: interleukin 3 and granulocyte/macrophage-colony-stimulating factor are specific for early developmental stages. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[25]  E. Clark,et al.  Adult-onset cyclic neutropenia is associated with increased large granular lymphocytes. , 1986, Blood.

[26]  J. Adamson,et al.  In vitro differentiation of human granulocyte/macrophage and erythroid progenitors: comparative analysis of the influence of recombinant human erythropoietin, G-CSF, GM-CSF, and IL-3 in serum-supplemented and serum-deprived cultures. , 1988, Blood.

[27]  Yu-Chung Yang,et al.  Human IL-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3 , 1986, Cell.

[28]  B. Calabretta,et al.  A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. , 1988, Science.

[29]  J. Adamson,et al.  Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Hammond,et al.  Adult-onset cyclic neutropenia is a benign neoplasm associated with clonal proliferation of large granular lymphocytes , 1986, The Journal of experimental medicine.

[31]  S Perry,et al.  Periodic hematopoiesis in human cyclic neutropenia. , 1973, The Journal of clinical investigation.

[32]  D. Dale,et al.  Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. , 1989, The New England journal of medicine.

[33]  J. Ihle,et al.  Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Kamen,et al.  The human hematopoietic colony-stimulating factors. , 1987, Science.

[35]  C. Peschle,et al.  Human embryonic hemopoiesis. Kinetics of progenitors and precursors underlying the yolk sac----liver transition. , 1986, The Journal of clinical investigation.